Patent · US Active

Induction of mucosal tolerance to antigens

US8748126B2 · kind B2 · utility

0Cited by

0References

33Claims

0Family size

Assignee

ACTOGENIX N.V. · BE

Inventors

Pieter Rottiers · Zevergem, BE
Veerle Snoeck · Zingem, BE

Key dates

Filing date	Nov 29, 2006
Grant date	Jun 10, 2014
Priority date	—
Expiry date	Jan 20, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/577
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells are induced which are capable of suppressing undesired immune responses toward an antigen. The antigen is preferably delivered orally in combination with an immunosuppressing cytokine secreting micro-organism.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.